open access

Vol 85, No 5 (2017)
CASE REPORTS
Published online: 2017-10-30
Submitted: 2017-07-11
Accepted: 2017-09-23
Get Citation

Sarcoidosis-associated pulmonary hypertension treated with sildenafil ― a case report

Aneta Kacprzak, Monika Szturmowicz, Barbara Burakowska, Monika Franczuk, Jarosław Kober, Marcin Kurzyna, Michał Wilk, Sebastian Szmit, Adam Torbicki, Jan Kuś
DOI: 10.5603/ARM.a2017.0042
·
Pubmed: 29083021
·
Adv Respir Med 2017;85(5):258-263.

open access

Vol 85, No 5 (2017)
CASE REPORTS
Published online: 2017-10-30
Submitted: 2017-07-11
Accepted: 2017-09-23

Abstract

Development of sarcoidosis-associated pulmonary hypertension (SAPH) significantly worsens prognosis in sarcoidosis patients. Unfortunately, there is no treatment of proven benefit for this condition. Medications used for treatment of pulmonary arterial hypertension are of great interest in this respect. Here, we report a case of a patient with severe SAPH treated with sildenafil. A significant, but only temporary improvement in functional status was observed, and the patient died of gradually progressing heart and respiratory failure while awaiting for lung transplantation.

Abstract

Development of sarcoidosis-associated pulmonary hypertension (SAPH) significantly worsens prognosis in sarcoidosis patients. Unfortunately, there is no treatment of proven benefit for this condition. Medications used for treatment of pulmonary arterial hypertension are of great interest in this respect. Here, we report a case of a patient with severe SAPH treated with sildenafil. A significant, but only temporary improvement in functional status was observed, and the patient died of gradually progressing heart and respiratory failure while awaiting for lung transplantation.

Get Citation

Keywords

sarcoidosis, pulmonary hypertension, treatment, sidlenafil

About this article
Title

Sarcoidosis-associated pulmonary hypertension treated with sildenafil ― a case report

Journal

Advances in Respiratory Medicine

Issue

Vol 85, No 5 (2017)

Pages

258-263

Published online

2017-10-30

DOI

10.5603/ARM.a2017.0042

Pubmed

29083021

Bibliographic record

Adv Respir Med 2017;85(5):258-263.

Keywords

sarcoidosis
pulmonary hypertension
treatment
sidlenafil

Authors

Aneta Kacprzak
Monika Szturmowicz
Barbara Burakowska
Monika Franczuk
Jarosław Kober
Marcin Kurzyna
Michał Wilk
Sebastian Szmit
Adam Torbicki
Jan Kuś

References (27)
  1. Statement on Sarcoidosis. American Journal of Respiratory and Critical Care Medicine. 1999; 160(2): 736–755.
  2. Rizzato G, Pezzano A, Sala G, et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis. 1983; 64(2): 121–128.
  3. Handa T, Nagai S, Fushimi Y, et al. Clinical and radiographic indices associated with airflow limitation in patients with sarcoidosis. Chest. 2006; 130(6): 1851–1856.
  4. Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005; 25(5): 783–788.
  5. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006; 61(1): 68–74.
  6. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest. 2003; 124(3): 922–928.
  7. Baughman RP, Engel PJ, Taylor L, et al. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010; 138(5): 1078–1085.
  8. Perez Vd. Faculty of 1000 evaluation for 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). F1000 - Post-publication peer review of the biomedical literature. .
  9. Lahm T, Chakinala MM. World Health Organization group 5 pulmonary hypertension. Clin Chest Med. 2013; 34(4): 753–778.
  10. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013; 62(25 Suppl): D109–D116.
  11. Gluskowski J, Hawrylkiewicz I, Zych D, et al. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J. 1990; 3(4): 403–407.
  12. Smith LJ, Lawrence JB, Katzenstein AA. Vascular sarcoidosis: a rare cause of pulmonary hypertension. Am J Med Sci. 1983; 285(1): 38–44.
  13. Takemura T, Matsui Y, Saiki S, et al. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol. 1992; 23(11): 1216–1223.
  14. Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant. 2008; 27(3): 329–334.
  15. Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest. 2009; 135(6): 1455–1461.
  16. Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2009; 26(2): 110–120.
  17. Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest. 2006; 130(5): 1481–1488.
  18. Bonham CA, Oldham JM, Gomberg-Maitland M, et al. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest. 2015; 148(4): 1055–1062.
  19. Dobarro D, Schreiber BE, Handler C, et al. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol. 2013; 111(2): 278–285.
  20. Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014; 145(4): 810–817.
  21. Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest. 2001; 120(3): 866–872.
  22. Judson MA, Highland KB, Kwon S, et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2011; 28(2): 139–145.
  23. Keir GJ, Walsh SLF, Gatzoulis MA, et al. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies. Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31(2): 82–90.
  24. Ford HJ, Baughman RP, Aris R, et al. Tadalafil therapy for sarcoidosis-associated pulmonary hypertension. Pulm Circ. 2016; 6(4): 557–562.
  25. Handa T, Nagai S, Ueda S, et al. Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010; 27(1): 27–35.
  26. Brewis MJ, Church AC, Johnson MK, et al. Severe pulmonary hypertension in lung disease: phenotypes and response to treatment. Eur Respir J. 2015; 46(5): 1378–1389.
  27. Hoeper MM, Behr J, Held M, et al. Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS One. 2015; 10(12): e0141911.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl